Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
Journal of Kidney Cancer and VHL
|
September 4, 2024
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials
Nathan Reynolds, Wei Wei, Kimberly Maroli, et al.
Targeted Oncology
|
August 11, 2021
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab
Kunal Desai, Landon Brown, Wei Wei, et al.
Clinical Genitourinary Cancer
|
September 15, 2016
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma
Moshe C Ornstein, Laura Wood, Paul Elson, et al.
Eye (London, England)
|
February 6, 2026
Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors
Nitesh Mohan, Sunil K Srivastava, Chandni Duphare, et al.
Clinical Genitourinary Cancer
|
August 18, 2020
Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration
Iris Y Sheng, Wei Wei, Yu-Wei Chen, et al.
Journal for Immunotherapy of Cancer
|
September 14, 2021
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
Landon C Brown, Kunal Desai, Wei Wei, et al.
Urologic Oncology
|
August 23, 2018
The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era
Yu-Wei Chen, Moshe C Ornstein, Laura S Wood, et al.
Targeted Oncology
|
November 6, 2021
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy
Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, et al.
Targeted Oncology
|
August 20, 2022
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors
Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, et al.
Journal for Immunotherapy of Cancer
|
May 18, 2019
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Moshe C Ornstein, Laura S Wood, Brian P Hobbs, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
Journal of Kidney Cancer and VHL
|
September 4, 2024
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials
Nathan Reynolds, Wei Wei, Kimberly Maroli, et al.
Targeted Oncology
|
August 11, 2021
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab
Kunal Desai, Landon Brown, Wei Wei, et al.
Clinical Genitourinary Cancer
|
September 15, 2016
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma
Moshe C Ornstein, Laura Wood, Paul Elson, et al.
Eye (London, England)
|
February 6, 2026
Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors
Nitesh Mohan, Sunil K Srivastava, Chandni Duphare, et al.
Clinical Genitourinary Cancer
|
August 18, 2020
Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration
Iris Y Sheng, Wei Wei, Yu-Wei Chen, et al.
Journal for Immunotherapy of Cancer
|
September 14, 2021
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
Landon C Brown, Kunal Desai, Wei Wei, et al.
Urologic Oncology
|
August 23, 2018
The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era
Yu-Wei Chen, Moshe C Ornstein, Laura S Wood, et al.
Targeted Oncology
|
November 6, 2021
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy
Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, et al.
Targeted Oncology
|
August 20, 2022
Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors
Iris Y Sheng, Shilpa Gupta, Chandana A Reddy, et al.
Journal for Immunotherapy of Cancer
|
May 18, 2019
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
Moshe C Ornstein, Laura S Wood, Brian P Hobbs, et al.
Page
of 7